Viking Therapeutics, Inc.

NasdaqCM:VKTX Stok Raporu

Piyasa değeri: US$8.1b

Viking Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Viking Therapeutics is forecast to grow earnings and revenue by 2.9% and 77.3% per annum respectively. EPS is expected to grow by 6.3% per annum. Return on equity is forecast to be -23% in 3 years.

Anahtar bilgiler

2.9%

Kazanç büyüme oranı

6.3%

EPS büyüme oranı

Biotechs kazanç büyümesi27.1%
Gelir büyüme oranı77.3%
Gelecekteki özkaynak getirisi-23.0%
Analist kapsamı

Good

Son güncelleme01 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Viking Therapeutics: Lots Of Positives

Oct 28

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics: Future Weight Loss Heavyweight?

Apr 02

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Jan 09
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Sep 21
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13
Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Viking Therapeutics announces senior management appointments

Jan 06

Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Dec 09
Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Viking Therapeutics: Progressing Steadily, But Concerns Remain

Nov 29

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:VKTX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202629-205-265-22010
12/31/20252-171-201-15811
12/31/2024N/A-108-100-8512
9/30/2024N/A-99-74-74N/A
6/30/2024N/A-97-72-72N/A
3/31/2024N/A-94-55-55N/A
12/31/2023N/A-86-73-73N/A
9/30/2023N/A-81-67-67N/A
6/30/2023N/A-74-61-61N/A
3/31/2023N/A-72-63-63N/A
12/31/2022N/A-69-48-48N/A
9/30/2022N/A-62-50-50N/A
6/30/2022N/A-59-47-47N/A
3/31/2022N/A-57-47-47N/A
12/31/2021N/A-55-48-48N/A
9/30/2021N/A-54-41-41N/A
6/30/2021N/A-50-35-35N/A
3/31/2021N/A-44-28-28N/A
12/31/2020N/A-39-22-22N/A
9/30/2020N/A-36-28-28N/A
6/30/2020N/A-32-26-26N/A
3/31/2020N/A-31-26-26N/A
12/31/2019N/A-26-25-25N/A
9/30/2019N/A-24-16-16N/A
6/30/2019N/A-24-18-18N/A
3/31/2019N/A-23-17-17N/A
12/31/2018N/A-22-19-19N/A
9/30/2018N/A-21-20-20N/A
6/30/2018N/A-20N/A-18N/A
3/31/2018N/A-19N/A-17N/A
12/31/2017N/A-21N/A-15N/A
9/30/2017N/A-20N/A-13N/A
6/30/2017N/A-18N/A-13N/A
3/31/2017N/A-16N/A-12N/A
12/31/2016N/A-15N/A-11N/A
9/30/2016N/A-16N/A-12N/A
6/30/2016N/A-17N/A-13N/A
3/31/2016N/A-21N/A-11N/A
12/31/2015N/A-23N/A-9N/A
9/30/2015N/A-17N/A-6N/A
6/30/2015N/A-12N/A-3N/A
3/31/2015N/A-27N/A-2N/A
12/31/2014N/A-22N/A-2N/A
9/30/2014N/A-23N/A-1N/A
6/30/2014N/A-23N/A-1N/A
3/31/2014N/A0N/A0N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VKTX is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: VKTX is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: VKTX is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: VKTX's revenue (77.3% per year) is forecast to grow faster than the US market (8.9% per year).

Yüksek Büyüme Geliri: VKTX's revenue (77.3% per year) is forecast to grow faster than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VKTX is forecast to be unprofitable in 3 years.


Büyüyen şirketleri keşfedin